THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 105 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2019. The put-call ratio across all filers is 56.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $668,690 | +2.6% | 78,855 | +8.6% | 0.00% | – |
Q1 2024 | $651,536 | -25.4% | 72,635 | -6.6% | 0.00% | – |
Q4 2023 | $873,741 | +30.2% | 77,735 | 0.0% | 0.00% | – |
Q3 2023 | $670,853 | -16.6% | 77,735 | 0.0% | 0.00% | – |
Q2 2023 | $804,557 | -4.6% | 77,735 | 0.0% | 0.00% | – |
Q1 2023 | $843,425 | -3.3% | 77,735 | 0.0% | 0.00% | – |
Q4 2022 | $872,187 | +10.7% | 77,735 | 0.0% | 0.00% | – |
Q3 2022 | $788,000 | +11.9% | 77,735 | 0.0% | 0.00% | – |
Q2 2022 | $704,000 | -5.2% | 77,735 | 0.0% | 0.00% | – |
Q1 2022 | $743,000 | -13.3% | 77,735 | +0.3% | 0.00% | – |
Q4 2021 | $857,000 | +63.9% | 77,535 | +9.6% | 0.00% | – |
Q3 2021 | $523,000 | -49.1% | 70,735 | 0.0% | 0.00% | – |
Q2 2021 | $1,027,000 | -28.9% | 70,735 | 0.0% | 0.00% | -100.0% |
Q1 2021 | $1,444,000 | +5.9% | 70,735 | -7.8% | 0.00% | 0.0% |
Q4 2020 | $1,364,000 | +20.2% | 76,735 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $1,135,000 | -30.7% | 76,735 | -1.7% | 0.00% | 0.0% |
Q2 2020 | $1,638,000 | +9.9% | 78,035 | +20.9% | 0.00% | 0.0% |
Q1 2020 | $1,491,000 | -10.3% | 64,535 | +0.5% | 0.00% | 0.0% |
Q4 2019 | $1,663,000 | +35.6% | 64,235 | +2.1% | 0.00% | 0.0% |
Q3 2019 | $1,226,000 | +19.3% | 62,935 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $1,028,000 | -28.0% | 62,935 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $1,427,000 | -11.4% | 62,935 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $1,611,000 | -22.5% | 62,935 | -1.1% | 0.00% | 0.0% |
Q3 2018 | $2,079,000 | +48.3% | 63,635 | +2.9% | 0.00% | 0.0% |
Q2 2018 | $1,402,000 | -3.0% | 61,835 | +3.7% | 0.00% | 0.0% |
Q1 2018 | $1,446,000 | -15.3% | 59,635 | -2.6% | 0.00% | 0.0% |
Q4 2017 | $1,708,000 | -18.6% | 61,235 | 0.0% | 0.00% | -50.0% |
Q3 2017 | $2,097,000 | -14.1% | 61,235 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $2,440,000 | +18.0% | 61,235 | +9.1% | 0.00% | 0.0% |
Q1 2017 | $2,067,000 | +13.3% | 56,135 | -1.9% | 0.00% | 0.0% |
Q4 2016 | $1,825,000 | -12.0% | 57,235 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $2,074,000 | +58.1% | 57,235 | -1.0% | 0.00% | +100.0% |
Q2 2016 | $1,312,000 | +113.3% | 57,839 | +76.7% | 0.00% | 0.0% |
Q1 2016 | $615,000 | +23.2% | 32,739 | +7.6% | 0.00% | – |
Q4 2015 | $499,000 | +49.0% | 30,439 | 0.0% | 0.00% | – |
Q3 2015 | $335,000 | -91.2% | 30,439 | -89.6% | 0.00% | -100.0% |
Q2 2015 | $3,812,000 | +21.6% | 292,777 | +62.0% | 0.00% | 0.0% |
Q1 2015 | $3,135,000 | +111.8% | 180,697 | +82.2% | 0.00% | +200.0% |
Q4 2014 | $1,480,000 | +13.4% | 99,170 | +75.2% | 0.00% | 0.0% |
Q3 2014 | $1,305,000 | -27.7% | 56,611 | -0.0% | 0.00% | -50.0% |
Q2 2014 | $1,805,000 | – | 56,634 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |